A Conditionally Replicating Adenovirus CNHK500 for the Treatment of Breast Cancer

Yue-min LI,San-tai SONG,Ze-fei JIANG,Jian-ming XU,Qi ZHANG,Ming-ying LI,Yan-zhen QIAN,Zhen-fu CUI,Qi-jun QIAN

DOI: https://doi.org/10.3872/j.issn.1007-385X.2005.02.010

2005-01-01

Abstract:Objective:To evaluate the selectively oncolytic effect of conditionally replicating adenovirus CNHK500 in breast cancer. Methods:We used virus proliferation assay cell viability assay to evaluate the proliferation and cytolysis selectivity of CNHK500. And we used Western-blot to confirm the expression of adenovirus CNHK500 E1A and E1B in cancer and normal cells. Results:The CNHK500 virus proliferation ability in breast cancer cell lines is similar to that of wtAd5, better than that of ONYX-015 virus. However, CNHK500 virus replicate 1000-fold less than that of wtAd5 in normal fibroblast cell lines. CNHK500 can effectively kill breast cancer cell, while it shows attenuated cytolysis in normal fi-broblast cells, with about 100-fold less than that of wtAd5. CNHK500 E1A is expressed in telomerase-positive breast cancer cells but not in lelomerase-negative normal fibroblast cells. E1B protein can be detected under hypoxia condition but not in normoxia conditions. Intravenous injections of CNHK500, yielded significant tumor growth delay in the telomer-ase-positive breast cancer xenografts though the MCF-7 represent a very fast growing tumor cell line. Antitumor efficacy of replication-competent adenovirus CNHK500 in vivo was associated with increased dosage of CNHK500. Conclusions:The results prove that CNHK500 has highly proliferation selectivity and potent cytolysis effect on breast cancer.